BACKGROUND AND OBJECTIVES: Acute kidney injury (AKI) is a frequent complication of cardiopulmonary bypass (CPB). Serum creatinine (SCr), the current standard, is an inadequate marker for AKI since a delay occurs before SCr rises. Biomarkers that are sensitive and rapidly measurable could allow early intervention and improve patient outcomes. We investigated the value of serum cystatin C as an early biomarker for AKI after pediatric CPB. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We analyzed data from 374 prospectively enrolled children undergoing CPB. Serum samples were obtained before and at 2, 12, and 24 hours after CPB. Cystatin C was quantified by nephelometry. The primary outcome was AKI, defined as a > or =50% increase in SCr. Secondary outcomes included severity and duration of AKI, hospital length of stay, and mortality. A multivariable stepwise logistic regression analysis was used to assess predictors of AKI. RESULTS: One hundred nineteen patients (32%) developed AKI using SCr criteria. Serum cystatin C concentrations were significantly increased in AKI patients at 12 hours after CPB (P < 0.0001) and remained elevated at 24 hours (P < 0.0001). Maximal sensitivity and specificity for prediction of AKI occurred at a 12-hour cystatin C cut-off of 1.16 mg/L. The 12-hour cystatin C strongly correlated with severity and duration of AKI as well as length of hospital stay. In multivariable analysis, 12-hour cystatin C remained a powerful independent predictor of AKI. CONCLUSION: Serum cystatin C is an early predictive biomarker for AKI and its clinical outcomes after pediatric CPB.
BACKGROUND AND OBJECTIVES:Acute kidney injury (AKI) is a frequent complication of cardiopulmonary bypass (CPB). Serum creatinine (SCr), the current standard, is an inadequate marker for AKI since a delay occurs before SCr rises. Biomarkers that are sensitive and rapidly measurable could allow early intervention and improve patient outcomes. We investigated the value of serum cystatin C as an early biomarker for AKI after pediatric CPB. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We analyzed data from 374 prospectively enrolled children undergoing CPB. Serum samples were obtained before and at 2, 12, and 24 hours after CPB. Cystatin C was quantified by nephelometry. The primary outcome was AKI, defined as a > or =50% increase in SCr. Secondary outcomes included severity and duration of AKI, hospital length of stay, and mortality. A multivariable stepwise logistic regression analysis was used to assess predictors of AKI. RESULTS: One hundred nineteen patients (32%) developed AKI using SCr criteria. Serum cystatin C concentrations were significantly increased in AKI patients at 12 hours after CPB (P < 0.0001) and remained elevated at 24 hours (P < 0.0001). Maximal sensitivity and specificity for prediction of AKI occurred at a 12-hour cystatin C cut-off of 1.16 mg/L. The 12-hour cystatin C strongly correlated with severity and duration of AKI as well as length of hospital stay. In multivariable analysis, 12-hour cystatin C remained a powerful independent predictor of AKI. CONCLUSION: Serum cystatin C is an early predictive biomarker for AKI and its clinical outcomes after pediatric CPB.
Authors: Stefan Herget-Rosenthal; Günter Marggraf; Johannes Hüsing; Frauke Göring; Frank Pietruck; Onno Janssen; Thomas Philipp; Andreas Kribben Journal: Kidney Int Date: 2004-09 Impact factor: 10.612
Authors: G Wernovsky; D Wypij; R A Jonas; J E Mayer; F L Hanley; P R Hickey; A Z Walsh; A C Chang; A R Castañeda; J W Newburger; D L Wessel Journal: Circulation Date: 1995-10-15 Impact factor: 29.690
Authors: Andrea Lassnigg; Daniel Schmidlin; Mohamed Mouhieddine; Lucas M Bachmann; Wilfred Druml; Peter Bauer; Michael Hiesmayr Journal: J Am Soc Nephrol Date: 2004-06 Impact factor: 10.121
Authors: Chirag R Parikh; Prasad Devarajan; Michael Zappitelli; Kyaw Sint; Heather Thiessen-Philbrook; Simon Li; Richard W Kim; Jay L Koyner; Steven G Coca; Charles L Edelstein; Michael G Shlipak; Amit X Garg; Catherine D Krawczeski Journal: J Am Soc Nephrol Date: 2011-08-11 Impact factor: 10.121
Authors: Amanda B Hassinger; Mark S Wainwright; Jerome C Lane; Shannon Haymond; Carl L Backer; Eric Wald Journal: Intensive Care Med Date: 2012-08-09 Impact factor: 17.440
Authors: Michael Zappitelli; Jason H Greenberg; Steven G Coca; Catherine D Krawczeski; Simon Li; Heather R Thiessen-Philbrook; Michael R Bennett; Prasad Devarajan; Chirag R Parikh Journal: JAMA Pediatr Date: 2015-06 Impact factor: 16.193
Authors: Asada Leelahavanichkul; Ana Carolina P Souza; Jonathan M Street; Victor Hsu; Takayuki Tsuji; Kent Doi; Lingli Li; Xuzhen Hu; Hua Zhou; Parag Kumar; Jürgen Schnermann; Robert A Star; Peter S T Yuen Journal: Am J Physiol Renal Physiol Date: 2014-08-20
Authors: Emily M Bucholz; Richard P Whitlock; Michael Zappitelli; Prasad Devarajan; John Eikelboom; Amit X Garg; Heather Thiessen Philbrook; Philip J Devereaux; Catherine D Krawczeski; Peter Kavsak; Colleen Shortt; Chirag R Parikh Journal: Pediatrics Date: 2015-03-09 Impact factor: 7.124